Earnings Pulse - Valeant Pharma Intl.

LONDON, November 7, 2014 /PRNewswire/ --

Investor-Edge.com has issued free earnings review on Valeant Pharmaceuticals International Inc. (NYSE: VRX). On October 20, 2014, the company reported its financial results for Q3 FY14 (period ended September 30, 2014). Click on www.investor-edge.com/FreeReports to read our free earnings review on Valeant Pharmaceuticals International Inc. (Valeant). During Q3 FY14, the pharmaceutical company's net revenue grew 33% on a Y-o-Y basis and its cash EPS saw an increase of 48% from the preceding year quarter. Our free coverage report can be accessed at:

www.investor-edge.com/register

Earnings Overview 

During Q3 FY14, Valeant reported overall revenue of $2.06 billion compared to $1.54 billion in the same period last year. The company's total revenues during the reported quarter met Bloomberg analysts' forecast of $2.06 billion. Valeant's total same store sales organic growth in Q3 FY14 was 19% on a Y-o-Y basis, including impact from generics. Further, Bausch & Lomb Holdings Inc., which was acquired by the company on August 05, 2013, saw organic growth of 12% on a Y-o-Y basis during Q3 FY14. The free research on VRX can be downloaded as in PDF format at:

www.Investor-Edge.com/VRXFreeReport

Valeant swung to profits in Q3 FY14, with GAAP net income of $275.40 million, or $0.81 per diluted share, as compared to GAAP net loss of $973.20 million, or a loss of $2.92 per diluted share, in the year-ago quarter. Analysts from Bloomberg had expected the company to report GAAP net income of $233.00 million, or $0.66 per diluted share, in Q3 FY14. The company's cash EPS increased to $2.11 per diluted share in Q3 FY14 from $1.43 per diluted share in the corresponding quarter last year. Additionally, the company's GAAP operating cash flow surged 207% Y-o-Y to $618.70 million and its adjusted operating cash flow grew 89% Y-o-Y to $771.40 million during Q3 FY14.

Commenting on the company's results, J. Michael Pearson, Chairman and CEO of Valeant, stated that the company delivered exceptional results for Q3 FY14 and exceeded its expectations on all key metrics. He said that with the acquisition of Bausch + Lomb and the impact of generics now behind, the true strength of the company's business and operating model is clearly visible by its financial results. The company's management has particularly been pleased to deliver over $600 million in GAAP operating cash flow to its shareholders, he added. Sign up and read the free analyst's notes on VRX at:

www.Investor-Edge.com/VRX-07112014

In its guidance for Q4 FY14, the company increased its cash EPS guidance between $2.45 and $2.55 and expects double-digit same store organic growth. Further, for FY14, Valeant's cash EPS has been updated to $8.22 to $8.32 to reflect Q3 FY14 outperformance and strong expected Q4 financial results.

Stock Performance 

On the day of the earnings release, October 20, 2014, Valeant' stock ended the session at $124.78, up 3.80%. While the stock has mostly witnessed a positive momentum since then, on the last close, Thursday, November 06, 2014, it finished at $128.77, 2.38% below its previous day's closing price. The stock vacillated between $128.38 and $132.79, and a total of 2.52 million shares were traded, which was below its three months average volume of 2.72 million shares. Over the previous three trading sessions, the company's shares have fallen by 3.07%. However, the stock has gained 0.28% over the last one month and 9.68% from the beginning of 2014. Shares in Valeant closed above their 50-day and 200-day moving averages of $123.85 and $127.38, respectively. Furthermore, the stock traded at a PE ratio of 40.88 and has a Relative Strength Index (RSI) of 59.99. Visit Investor-Edge and access the latest research on VRX at:

www.Investor-Edge.com/VRXEarningsCoverage

Sneak Peek to Corporate Insider Trading 

In the last one month Valeant has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on VRX is available at:

www.Investor-Edge.com/VRXInsiderTrading

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED